Pathology in France: Colorectal Cancer

• Publication date: November 2010

The report is an essential source of information and analysis on the French colorectal cancer therapeutics industry . The report provides comprehensive data on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the major industry developments shaping and driving the French colorectal cancer therapeutics industry . It analyses the treatment usage patterns in the French colorectal cancer therapeutics industry . The...

The report is an essential source of information and analysis on the French colorectal cancer therapeutics industry . The report provides comprehensive data on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the major industry developments shaping and driving the French colorectal cancer therapeutics industry . It analyses the treatment usage patterns in the French colorectal cancer therapeutics industry . The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The report provides valuable insights into the new product development within the global colorectal cancer segment . It quantifies the unmet need in the French colorectal cancer therapeutics industry, highlighting the opportunity for future players.


Scope of the Research

The

Scope of the Research of the report includes:
- An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized French colorectal cancer therapeutics industry revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, projection for 11 years to 2020.
- Insightful review of the key market drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales projections .
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales projection .
- Analysis of unmet need in the industry and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
- An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, industry ing rights and launch analysis.
- Analysis of the current and future industry competition in the French Colorectal Cancer therapeutics industry . Firms profiles including business description, financial overview and SWOT analysis. Key future industry players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
- Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics industry . Merger and Acquisition analysis which includes Merger and Acquisition deals by size and geography.
- Strategic assessment of the industry through industry impact analysis, future industry scenario and industry player analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics industry in France.

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior industry quantification analysis by
- Understanding the trends shaping and driving the French colorectal cancer therapeutics industry .
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing industry sizing, projections and quantified growth opportunities in the French colorectal cancer therapeutics industry till 2020.
- Quantifying patient population in France to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and industry ing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently industry ed products
- Identifying industry entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in industry by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the French colorectal cancer therapeutics industry from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the French Colorectal Cancer therapeutics industry landscape? Identify, understand and decide.

Therapy Industry in France

List of Figures
List of Tables

I Colorectal Cancer: Executive Summary
I. 1 The Colorectal Cancer Therapeutics March ket in France was Worth US$ 0.7 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy
I. 2 The Current Competition in the Colorectal Cancer Therapeutics March ket in France is Weak as None of the Drugs Completely Addressed the Unmet Needs
I. 3 The Colorectal Cancer Pipeline is Strong with Many November el First-in-class Molecules in Late-stage Clinical Development
I. 4 High Unmet Needs Exist in the French Colorectal Cancer Therapeutics March ket in terms of Efficacy and Safety
2 Disease Data
II. 1 Overview
II. 2 Epidemiology
II. 3 Etiology
II. 4 Symptoms
II. 4.1 Colon Cancer
II. 4.2 Rectal Cancer
II. 5 Diagnosis
II. 5.1 FOBT
II. 5.1.1 Sensitivity
II. 5.2 Endoscopy
II. 5.2.1 Sigmoidoscopy
II. 5.2.2 Sensitivity
II. 5.3 Optical Colonoscopy
II. 5.3.1 Sensitivity
II. 5.4 Virtual Colonoscopy
II. 5.4.1 Sensitivity
II. 5.5 Double Contrast Barium Enema (DCBE)
II. 5.5.1 Sensitivity
II. 6 Pathology
II. 6.1 Grading
II. 7 Treatment
II. 7.1 Colon Cancer Treatment by Stage
II. 7.2 Rectal Cancer Treatment by Stage
II. 7.3 Chemotherapy Options
II. 7.3.1 Adjuvant Treatment
II. 7.3.2 First-line Treatment
II. 7.3.3 Second-line Treatment
II. 7.3.4 Third-line Treatment
II. 8 Treatment Guidelines

III March ket Characterization
III. 1 France
III. 1.1 March ket Size
III. 1.1.1 Sales Value
III. 1.1.2 Annual Cost of Therapy
III. 1.1.3 Patient Volume
III. 1.1.4 Treatment Usage Patterns
III. 1.2 Drivers and Barriers
III. 1.2.1 Drivers of France Colorectal Cancer March ket
III. 1.2.2 Restraints of France colorectal Cancer March ket
III. 1.3 Impact on the March ket
III. 1.4 Forecasted data s
III. 1.4.1 Sales Value
III. 1.4.2 Annual Cost of Therapy
III. 1.4.3 Patient Volume
III. 1.4.4 Treatment Usage Patterns
III. 1.4.5 Future Impact
III. 1.5 Drug Sales
III. 1.5.1 Overview
III. 1.6 Pricing & Reimbursements
III. 1.6.1 Pricing of Drugs in France
III. 1.6.2 Reimbursement Policy in France
III. 2 Key Takeaway

IV Competitor Assessment
IV. 1 Strategic Competitor Assessment
IV. 1.1 Overview
IV. 1.2 Benchmarking
IV. 1.2.1 Clinical Endpoints Benchmarking
IV. 1.2.2 Safety Profile
IV. 1.2.3 Annual Cost of Therapy
IV. 1.3 Current Competitor Assessment
IV. 2 Launch Analysis and Sales Forecasted data s
IV. 2.1 March ket Share Analysis of Drugs
IV. 3 Product Profiles
IV. 3.1 Avastin (bevacizumab)
IV. 3.1.1 Overview
IV. 3.1.2 Efficacy
IV. 3.1.3 Safety
IV. 3.1.4 Clinical Study Details
IV. 3.1.5 Annual Cost of Therapy
IV. 3.1.6 Regulatory Approvals
IV. 3.1.7 Life Cycle Management Activities
IV. 3.1.8 Product Positioning
IV. 3.1.9 Sales Forecasted data
IV. 3.2 Erbitux (cetuximab)
IV. 3.2.1 Overview
IV. 3.2.2 Efficacy
IV. 3.2.3 Safety
IV. 3.2.4 Clinical Study Details
IV. 3.2.5 Annual Cost of Therapy
IV. 3.2.6 Regulatory Approvals
IV. 3.2.7 Life Cycle Management Activities
IV. 3.2.8 Product Positioning
IV. 3.2.9 Sales Forecasted data
IV. 3.3 Xeloda (capecitabine)
IV. 3.3.1 Overview
IV. 3.3.2 Efficacy
IV. 3.3.3 Safety
IV. 3.3.4 Clinical Study Details
IV. 3.3.5 Regulatory Approvals
IV. 3.3.6 Life Cyle Management Activities
IV. 3.3.7 Annual Cost of Therapy
IV. 3.3.8 Product Positioning
IV. 3.3.9 Sales Forecasted data
IV. 3.4 Vectibix (panitumumab)
IV. 3.4.1 Overview
IV. 3.4.2 Efficacy
IV. 3.4.3 Safety
IV. 3.4.4 Clinical Study Details
IV. 3.4.5 Regulatory Approvals
IV. 3.4.6 Life Cyle Management Activities
IV. 3.4.7 Annual Cost of Therapy
IV. 3.4.8 Product Positioning
IV. 3.4.9 Sales Forecasted data
IV. 3.5 Eloxatin (oxaliplatin)
IV. 3.5.1 Overview
IV. 3.5.2 Efficacy
IV. 3.5.3 Safety
IV. 3.5.4 Clinical Study Details
IV. 3.5.5 Regulatory Approvals
IV. 3.5.6 Life Cyle Management Activities
IV. 3.5.7 Annual Cost of Therapy
IV. 3.5.8 Product Positioning
IV. 3.5.9 Sales Forecasted data
IV. 3.6 Camptosar (irinotecan)
IV. 3.6.1 Overview
IV. 3.6.2 Efficacy
IV. 3.6.3 Safety
IV. 3.6.4 Clinical Study Details
IV. 3.6.5 Annual cost of Therapy
IV. 3.6.6 Regulatory approvals
IV. 3.6.7 Life Cyle Management Activities
IV. 3.6.8 Sales projection
IV. 3.7 Fluorouracil (5-FU)
IV. 3.7.1 Overview
IV. 3.7.2 Efficacy
IV. 3.7.3 Safety
IV. 3.7.4 Annual Cost of Therapy
IV. 3.8 Leucovorin (folinic acid)
IV. 3.8.1 Overview
IV. 3.8.2 Efficacy
IV. 3.8.3 Safety
IV. 3.8.4 Annual Cost of Therapy
IV. 4 Key Takeaway

V Pipeline Assessment
V. 1 Overview
V. 2 Pipeline Analysis by Phase of Development
V. 3 Pipeline by Mechanism of Action
V. 4 Strategic Pipeline Assessment
V. 4.1 Technology Trends Analytical Framework
V. 5 Trends in Colorectal Cancer Pipeline
V. 5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer
V. 5.2 November el First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline
V. 5.3 Failure of key Molecules in Phase II and Phase III Development
V. 6 Partners in Development
V. 6.1 Licensing Agreements by Phase of Development
V. 6.1.1 Morphotek Enters Into Exclusive License Agreement with National Cancer Institute
V. 6.1.2 AVEO Pharmaceuticals Enters Into Licensing Agreement with Kirin Brewery
V. 6.1.3 Access Pharmaceuticals Enters Into Licensing Agreement with Jiangsu Aosaikang Pharmaceutical
V. 6.1.4 Merck Enters Into Licensing Agreement with Taiho Pharmaceutical
V. 6.1.5 Rexahn Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical
V. 6.1.6 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
V. 6.2 Licensing Agreements by Geography
V. 6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
V. 7 Most Promising Drugs’ Profiles
V. 7.1 Aflibercept
V. 7.1.1 Overview
V. 7.1.2 Efficacy
V. 7.1.3 Safety
V. 7.1.4 Clinical Study Details
V. 7.1.5 Collaboration Agreements
V. 7.1.6 March keting Rights
V. 7.1.7 Launch Analysis
V. 7.1.8 Sales Forecasted data
V. 7.2 Brivanib
V. 7.2.1 Overview
V. 7.2.2 Efficacy
V. 7.2.3 Safety
V. 7.2.4 Clinical trials
V. 7.2.5 Collaboration Agreements
V. 7.2.6 March keting Rights
V. 7.2.7 Launch Analysis
V. 7.2.8 Sales Forecasted data
V. 7.3 OncoVAX
V. 7.3.1 Overview
V. 7.3.2 Efficacy
V. 7.3.3 Safety
V. 7.3.4 Clinical Trials
V. 7.3.5 Collaboration Agreements
V. 7.3.6 March keting Rights
V. 7.3.7 Launch Analysis
V. 7.3.8 Sales Forecasted data
V. 7.4 TroVax
V. 7.4.1 Overview
V. 7.4.2 Efficacy
V. 7.4.3 Safety
V. 7.4.4 Clinical Study Details
V. 7.4.5 Collaboration Agreements
V. 7.4.6 March keting Rights
V. 7.4.7 Launch Analysis
V. 7.4.8 Sales Forecasted data
V. 7.5 KRX-0401 (Perifosine)
V. 7.5.1 Overview
V. 7.5.2 Efficacy
V. 7.5.3 Safety
V. 7.5.4 Clinical Study Details
V. 7.5.5 Collaboration Agreements
V. 7.5.6 March keting Rights
V. 7.5.7 Launch Analysis
V. 8 Colorectal Cancer Pipeline – Preclinical Phase
V. 9 Colorectal Cancer Pipeline – Phase I
V. 10 Colorectal Cancer Pipeline – Phase II
V. 11 Colorectal Cancer Pipeline – Phase III
V. 12 Key Takeaway

VI Unmet Need
VI. 1 Opportunity for Target Product
VI. 2 Target Product Profile
VI. 2.1 Ideal Characteristics
VI. 2.2 Target Product Description
VI. 3 Key Takeaway

VII Strategic Assessment
VII. 1 Key Events Impacting the Future March ket
VII. 2 March ket Impact Analysis
VII. 3 Future March ket Scenario
VII. 4 Firms Analysis
VII. 4.1 March ket Leadership
VII. 4.2 Future Players in the March ket
VII. 5 Key Takeaway

VIII Company Profiles
VIII. 1 F. Hoffmann La Roche
VIII. 1.1 Business Overview
VIII. 1.2 Financial Overview
VIII. 1.3 SWOT
VIII. 1.3.1 Strengths (SWOT Analysis)
VIII. 1.3.2 Weakness
VIII. 1.3.3 Opportunities (SWOT Analysis)
VIII. 1.3.4 Threats (SWOT Analysis)
VIII. 2 Bristol-Myers Squibb
VIII. 2.1 Business Overview
VIII. 2.2 Financial Overview
VIII. 2.3 SWOT
VIII. 2.3.1 Strengths (SWOT Analysis)
VIII. 2.3.2 Weakness
VIII. 2.3.3 Opportunities (SWOT Analysis)
VIII. 2.3.4 Threats (SWOT Analysis)
VIII. 3 Sanofi-Aventis
VIII. 3.1 Business Overview
VIII. 3.2 Financial Overview
VIII. 3.3 SWOT
VIII. 3.3.1 Strengths (SWOT Analysis)
VIII. 3.3.2 Weakness
VIII. 3.3.3 Opportunities (SWOT Analysis)
VIII. 3.3.4 Threats (SWOT Analysis)
VIII. 4 Debiopharm Group
VIII. 4.1 Business Overview
VIII. 5 Merck KGaA
VIII. 5.1 Business Overview
VIII. 5.2 Financial Overview
VIII. 5.3 SWOT
VIII. 5.3.1 Weakness
VIII. 5.3.2 Opportunities (SWOT Analysis)
VIII. 5.3.3 Threats (SWOT Analysis)
VIII. 6 Regeneron
VIII. 6.1 Business Overview
VIII. 6.2 Financial Overview
VIII. 6.3 SWOT
VIII. 6.3.1 Strengths (SWOT Analysis)
VIII. 6.3.2 Weakness
VIII. 6.3.3 Opportunities (SWOT Analysis)
VIII. 6.3.4 Threats (SWOT Analysis)
VIII. 7 Vaccinogen BD
VIII. 7.1 Overview
VIII. 7.2 SWOT
VIII. 7.2.1 Strengths (SWOT Analysis)
VIII. 7.2.2 Opportunities (SWOT Analysis)
VIII. 8 Oxford BioMedica
VIII. 8.1 Business Overview
VIII. 8.2 Financial Overview
VIII. 8.3 SWOT
VIII. 8.3.1 Strengths (SWOT Analysis)
VIII. 8.3.2 Weakness
VIII. 8.3.3 Opportunities (SWOT Analysis)
VIII. 9 Auron Healthcare GmbH
VIII. 9.1 Company Profile
VIII. 10 AEterna Zentaris
VIII. 10.1 Business Overview
VIII. 10.2 Financial Overview
VIII. 10.3 SWOT
VIII. 10.3.1 Strengths (SWOT Analysis)
VIII. 10.3.2 Weakness
VIII. 10.3.3 Opportunities (SWOT Analysis)
VIII. 10.3.4 Threats (SWOT Analysis)
VIII. 11 Keryx
VIII. 11.1 Business Overview
VIII. 11.2 Financial Overview
VIII. 11.3 SWOT Anlaysis
VIII. 11.3.1 Strengths (SWOT Analysis)
VIII. 11.3.2 Weakness
VIII. 11.3.3 Opportunities (SWOT Analysis)
VIII. 11.3.4 Threats (SWOT Analysis)
VIII. 12 Abbott Laboratories
VIII. 12.1 Business Overview
VIII. 12.2 Financial Performance
VIII. 12.3 SWOT
VIII. 12.3.1 Strengths (SWOT Analysis)
VIII. 12.3.2 Weaknesses (SWOT Analysis)
VIII. 12.3.3 Opportunities (SWOT Analysis)
VIII. 12.3.4 Threats (SWOT Analysis)
VIII. 13 Pfizer
VIII. 13.1 Business Overview
VIII. 13.2 Financial Overview
VIII. 13.3 SWOT
VIII. 13.3.1 Strengths (SWOT Analysis)
VIII. 13.3.2 Weaknesses (SWOT Analysis)
VIII. 13.3.3 Opportunities (SWOT Analysis)
VIII. 13.3.4 Threats (SWOT Analysis)
VIII. 14 Light Sciences Oncology, Inc
VIII. 14.1 Business Overview
VIII. 14.2 Financial Overview
VIII. 14.3 SWOT
VIII. 14.3.1 Strength
VIII. 14.3.2 Weakness
VIII. 14.3.3 Opportunities (SWOT Analysis)
VIII. 14.3.4 Threats (SWOT Analysis)

IX Deals Analysis
IX. 1 Key Highlights
IX. 2 Key Deals’ Analysis
IX. 2.1 Eli Lilly Takes Over ImClone
IX. 2.2 Astellas Pharma Takes Over OSI Pharmaceuticals
IX. 2.3 Takeda Takes Over IDM Pharma
IX. 2.4 Alchemia Takes Over Meditech
IX. 2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron
IX. 2.6 BBM Holdings to Acquire YM Biosciences
IX. 2.7 Pfizer Takes Over Assets of Campto from Sanofi-Aventis
IX. 2.8 Peptech Takes Over cancer Antibodies from Scancell
IX. 2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs
IX. 2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc
IX. 3 Deals Analysis by Geography
IX. 4 Deals Analysis by Deal Size

X Appendix
X. 1 March ket Definitions
X. 2 Abbreviations
X. 3 Research Methodology
X. 3.1 Coverage
X. 3.2 Secondary Research
X. 3.3 Forecasted data ing
X. 3.3.1 Epidemiology-based Forecasted data ing
Analogous Forecasted data ing Methodology
Diseased Population
Treatment Seeking Population
Diagnosis Population
Prescription Population
Forecasting Model for Therapeutic Areas
X. 3.4 Primary Research
X. 3.5 Expert Panel validation
X. 3.6 Contact Us
X. 3.7 Disclaimer
X. 3.8 Sources

Data table 1: Colorectal Cancer Therapeutics March ket, Global, Staging of Colorectal Cancer, 2010
Data table 2: Colorectal Cancer Therapeutics March ket, Global, WHO Classification of Colorectal Carcinomas, 2010
Data table 3: Colorectal Cancer Therapeutics March ket, France, Sales Value ($), 2001–2009
Data table 4: Colorectal Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), 2001–2009
Data table 5: Colorectal Cancer Therapeutics March ket, France, Patient Volume (’000), 2001–2009
Data table 6: Colorectal Cancer Therapeutics March ket, France, Treatment Usage Patterns, 2001–2009
Data table 7: Colorectal Cancer Therapeutics March ket, France, Sales Value ($bn), 2009–2020
Data table 8: Colorectal Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), 2009–2020
Data table 9: Colorectal Cancer Therapeutics March ket, France, Patient Volume (’000), 2009–2020
Data table 10: Colorectal Cancer Therapeutics March ket, France, Treatment Usage Patterns, 2009–2020
Data table 11: Colorectal Cancer Therapeutics March ket, France, Drug Sales (USD Million), from 2001 to 2010
Data table 12: Colorectal Cancer Therapeutics March ket, France, Drug Sales (USD Million), from 2011 to 2020
Data table 13: Colorectal Cancer, Global, Safety Company Profile: Standard Treatment, 2010
Data table 14: Colorectal Cancer Therapeutics March ket, Global, Benchmarking Major March keted Products, 2010
Data table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010
Data table 16: Colorectal Cancer Therapeutics March ket, Global, Erbitux, Incidence of Adverse Effects, 2010
Data table 17: Colorectal Cancer Therapeutics March ket, Global, Xeloda, Adverse Effects Incidence, 2010
Data table 18: Colorectal Cancer Therapeutics March ket, Global, Vectibix, PRECEPT Interim Results, 2010
Data table 19: Colorectal Cancer Therapeutics March ket, Global, Vectibix, Incidence of Adverse Events, 2010
Data table 20: Colorectal Cancer Therapeutics March ket, Global, Eloxatin, Efficacy, 2010
Data table 21: Colorectal Cancer Therapeutics March ket, Global, Eloxatin, Incidence of Adverse Events, 2010
Data table 22: Colorectal Cancer Therapeutics March ket, Global, Technology Licensing Agreements Description, 2010
Data table 23: Colorectal Cancer Therapeutics March ket, Global, Preclinical Phase Pipeline, 2010
Data table 24: Colorectal Cancer, Global, Phase I Pipeline, 2010
Data table 25: Colorectal Cancer, Global, Phase II Pipeline, 2010
Data table 26: Colorectal Cancer, Global, Phase III Pipeline, 2010
Data table 27: Colorectal Cancer Therapeutics March ket, Global, Commonly Prescribed Treatment Options, 2010
Data table 28: Colorectal Cancer Therapeutics March ket, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010
Data table 29: Colorectal Cancer Therapeutics March ket, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010

Chart 1: Colorectal Cancer Therapeutics March ket, France, Sales Value ($bn), from 2001 to 2020
Chart 2: Colorectal Cancer Therapeutics March ket, Global, Pipeline by Mechanism of Action, 2010
Chart 3: Colorectal Cancer Therapeutics March ket, France, Opportunity and Unmet Need, 2009
Chart 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010
Chart 5: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010
Chart 6: Colorectal Cancer Therapeutics March ket, France, Sales Value ($bn), 2001–2009
Chart 7: Colorectal Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), 2001–2009
Chart 8: Colorectal Cancer Therapeutics March ket, France, Patient Volume, 2001–2009
Chart 9: Colorectal Cancer Therapeutics March ket, France, Treatment Usage Patterns, 2001–2009
Chart 10: Colorectal Cancer Therapeutics March ket, France, March ket Drivers and Restraints, 2009
Chart 11: Colorectal Cancer Therapeutics March ket, France, The Impact of Historical data al Events on the March ket, 2010
Chart 12: Colorectal Cancer Therapeutics March ket, France, Sales Value ($bn), 2009–2020
Chart 13: Colorectal Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), 2009–2020
Chart 14: Colorectal Cancer Therapeutics March ket, France, Patient Volume, 2009–2020
Chart 15: Colorectal Cancer Therapeutics March ket, France, Treatment Usage Patterns, 2009–2020
Chart 16: Colorectal Cancer Therapeutics March ket, France, Future March ket Drivers and Restraints, 2009–2020
Chart 17: Colorectal Cancer Therapeutics March ket, France, Drug Sales (USD Million), from 2001 to 2020
Chart 18: Colorectal Cancer Therapeutics March ket, Global, Clinical Endpoints for Benchmarking, 2010
Chart 19: Colorectal Cancer Therapeutics March ket, Global, Strategic Competitor Assessment of Major March keted Drugs, 2010
Chart 20: Colorectal Cancer Therapeutics March ket, France, Sales Forecasted data Split by Therapies, from 2001 to 2020
Chart 21: Colorectal Cancer Therapeutics March ket, Global, Avastin, Life Cycle Management Activities, 2004–2010
Chart 22: Colorectal Cancer Therapeutics March ket, France, Avastin, Sales Forecasted data (USD Million), from 2005 to 2020
Chart 23: Colorectal Cancer Therapeutics March ket, Global, Erbitux, Life Cycle Management Activities, 2004–2010
Chart 24: Colorectal Cancer Therapeutics March ket, Global, Erbitux, Sales Forecasted data (USD Million), from 2004 to 2020
Chart 25: Colorectal Cancer Therapeutics March ket, Global, Xeloda, Chemical Structure, 2010
Chart 26: Colorectal Cancer Therapeutics March ket, Global, Xeloda, Life Cycle Management Activities, 2010
Chart 27: Colorectal Cancer Therapeutics March ket, France, Xeloda, Sales Forecasted data (USD Million), from 2001 to 2020
Chart 28: Colorectal Cancer Therapeutics March ket, Global, Vectibix, Life Cyle Management Activities, 2010
Chart 29: Colorectal Cancer Therapeutics March ket, France, Vectibix, Sales Forecasted data (USD Million), from 2008 to 2020
Chart 30: Colorectal Cancer Therapeutics March ket, Global, Eloxatin, Chemical Structure, 2010
Chart 31: Colorectal Cancer Therapeutics March ket, Global, Eloxatin, Life Cyle Management Activities, 2010
Chart 32: Colorectal Cancer Therapeutics March ket, France, Eloxatin, Sales Forecasted data (USD Million), from 2001 to 2020
Chart 33: Colorectal Cancer Therapeutics March ket, Global, Camptosar, Chemical Structure
Chart 34: Colorectal Cancer Therapeutics March ket, Global, Camptosar, Life Cyle Management Activities, 2010
Chart 35: Colorectal Cancer Therapeutics March ket, France, Camptosar, Sales Forecasted data (USD Million), from 2001 to 2020
Chart 36: Colorectal Cancer Therapeutics March ket, Global, Fluorouracil, Chemical Structure
Chart 37: Colorectal Cancer Therapeutics March ket, Global, Leucovorin, Chemical Structure
Chart 38: Colorectal Cancer Therapeutics March ket, Global, Clinical Trials by Therapy (%), 2010
Chart 39: Colorectal Cancer Therapeutics March ket, Global, Clinical Trials by Phase of Development (%), 2010
Chart 40: Colorectal Cancer Therapeutics March ket, Global, Pipeline by Mechanism of Action, 2010
Chart 41: Colorectal Cancer Therapeutics March ket, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
Chart 42: Colorectal Cancer Therapeutics March ket, Global, Technology Trends Description of Pipeline Drugs, 2010
Chart 43: Colorectal Cancer Therapeutics March ket, Global, Licensing Agreements by Phase of Development (%), from 2004 to 2010
Chart 44: Colorectal Cancer Therapeutics March ket, Global, Licensing Agreements by Geography (%), 2010
Chart 45: Colorectal Cancer Therapeutics March ket, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010
Chart 46: Colorectal Cancer Therapeutics March ket, France, Aflibercept Sales Forecasted data (USD Million), from 2011 to 2020
Chart 47: Colorectal Cancer Therapeutics March ket, Global, Brivanib Chemical Structure, 2010
Chart 48: Colorectal Cancer Therapeutics March ket, France, Brivanib Sales Forecasted data s (USD Million), 2013-2020
Chart 49: Colorectal Cancer Therapeutics March ket, France, OncoVAX Sales Forecasted data (USD Million), from 2011 to 2020
Chart 50: Colorectal Cancer Therapeutics March ket, France, TroVax Sales Forecasted data (USD Million), 2014-2020
Chart 51: Colorectal Cancer Therapeutics March ket, Global, Perifosine Chemical Structure, 2010
Chart 52: Colorectal Cancer Therapeutics March ket, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010
Chart 53: Colorectal Cancer Therapeutics March ket, Global, Opportunity and Unmet Need, 2010
Chart 54: Colorectal Cancer, Global, Key Events Impacting the Future March ket
Chart 55: Colorectal Cancer Therapeutics March ket, Global, Implications for Future March ket Competition, 2010
Chart 56: Colorectal Cancer Therapeutics March ket, Global, Merger and Acquisition Deals by Geography, 2010
Chart 57: Colorectal Cancer Therapeutics March ket, Global, Merger and Acqusition Deals by Geography (%), 2010
Chart 58: Colorectal Cancer Therapeutics March ket, Global, Merger and Acquisition Deals by Deal Size (%), 2010
Chart 65: GlobalData March ket Forecasted data ing Model